StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a report released on Wednesday morning. The firm issued a sell rating on the stock.
Ayala Pharmaceuticals Price Performance
Ayala Pharmaceuticals stock opened at $0.56 on Wednesday. The stock’s 50-day moving average is $0.69 and its 200-day moving average is $0.74. The company has a market cap of $5.97 million, a price-to-earnings ratio of -0.07 and a beta of 1.62. Ayala Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $1.95.
Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) last announced its earnings results on Tuesday, April 16th. The company reported ($2.96) EPS for the quarter.
Ayala Pharmaceuticals Company Profile
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.
Recommended Stories
- Five stocks we like better than Ayala Pharmaceuticals
- 3 Best Fintech Stocks for a Portfolio Boost
- MarketBeat Week in Review – 4/22 – 4/26
- What is the Euro STOXX 50 Index?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Why Invest in High-Yield Dividend Stocks?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
